Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Core Insights - Ventyx Biosciences announced positive preclinical data for its NLRP3 inhibitor VTX3232, showing improvements in body weight, systemic inflammatory biomarkers, and cardiometabolic parameters in diet-induced obesity (DIO) mice [1][2] Study Findings - In DIO Study 1, VTX3232 monotherapy resulted in reduced body weight, body fat content, food consumption, liver triglycerides, and liver fat deposits, along with improvements in insulin resistance and cardiometabolic parameters [2][8] - DIO Study 2 demonstrated that the combination of VTX3232 with the GLP-1 receptor agonist semaglutide produced additive effects, leading to greater reductions in body weight, liver steatosis, and metabolic parameters compared to either treatment alone [2][8] - Systemic inflammatory biomarkers such as IL-1β, IL-6, and fibrinogen were significantly reduced in the plasma of DIO mice treated with VTX3232, with further reductions observed in the combination therapy group [8] Future Plans - The company plans to initiate a Phase 2a trial of VTX3232 in participants with obesity and cardiovascular risk factors in the second half of 2024 [2] - Comprehensive results from the studies will be submitted for future publication or presentation in a scientific forum [5]